Login to Your Account



Xention Inks Servier Option Deal for Ion Channel Modulator

By Nuala Moran
Staff Writer

Wednesday, October 9, 2013
LONDON – Xention Ltd. has taken a major step forward, out-licensing its atrial fibrillation treatment XEN-DO103 in a $163 million-plus joint development agreement in which the UK biotech will retain full rights to the product in the U.S. and Japan.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription